key: cord-0962782-2c5to8n1
authors: Harris, Asaf; Al Mushref, Mazen
title: Graves’ Thyrotoxicosis following SARS-CoV-2 Infection
date: 2020-12-28
journal: AACE Clin Case Rep
DOI: 10.1016/j.aace.2020.12.005
sha: 21320f7290570eba148221f8724adb0a556d17d6
doc_id: 962782
cord_uid: 2c5to8n1

OBJECTIVE: Graves’ disease (GD) is an autoimmune thyroid disease thought to develop following environmental exposure in patients with genetic predisposition. Our objective is to present the first report of GD onset immediately following recovery from mild coronavirus disease 2019 (COVID-19), a close temporal occurrence which should be studied further. METHODS: We describe the clinical course and laboratory features, including thyroid function studies, antibody testing, and PCR testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RESULTS: A 21-year-old woman with pre-diabetes, obesity, asthma, and GERD presented to the emergency department (ED) reporting three days of tachycardia, palpitations, anxiety, and shortness of breath.. Laboratory investigation revealed a TSH level of 0.01 mcIU/mL (0.30-5.00 mcIU/mL) with free T4 3.8 ng/dL (0.6-1.6 ng/dL),prompting Endocrinology consultation. On physical exam she had mild diffuse thyromegaly without tenderness, and history included hypothyroidism in her mother. Antibody testing results demonstrated thyroid stimulating immunoglobulin 2.6 (< 1.3 TSI index) and thyrotropin receptor antibody 17 IU/L (0.00-1.75 IU/L). Sixteen days before presenting to ED she was diagnosed with COVID-19 by PCR test after reporting typical symptoms including fever. Infectious symptoms resolved within ten days. She achieved clinical and laboratory improvement with a combination of methimazole and beta blocker therapy. CONCLUSION: This case documents the occurrence of Graves’ thyrotoxicosis following mild symptomatic COVID-19. Whether the preceding infection is coincidental or contributed to GD development requires definitive studies. This presentation may align with the theory of a viral link in the development of autoimmune thyroid disease in those with genetic predisposition.

physical exam she had mild diffuse thyromegaly without tenderness, and history included 23 hypothyroidism in her mother. Antibody testing results demonstrated thyroid stimulating 24 immunoglobulin 2.6 (< 1.3 TSI index) and thyrotropin receptor antibody 17 IU/L (0.00-1.75 25 IU/L). Sixteen days before presenting to ED she was diagnosed with COVID-19 by PCR test after 26 reporting typical symptoms including fever. Infectious symptoms resolved within ten days. She including exposure to iodine, medications, stress, smoking, and certain viral infections (2,3). 41 We describe a previously unreported case of GD development in close temporal occurrence to 42 COVID-19 infection. .01 mcIU/mL (0.30-5.00 mcIU/mL) with free T4 3.8 ng/dL (0.6-1.6 ng/dL). These results were 75 conveyed to our Endocrinology practice and she was scheduled for urgent consultation. 76 Notably, the patient had normal TSH results one year and five years prior to presentation (Table   77 1). At follow-up the patient reported palpitations and shortness of breath with minimal 78 exertion, as well as heat intolerance with excessive sweating and increased anxiety. On physical 79 exam she was tachycardic. Mild diffuse thyromegaly without tenderness was present, as well as 80 fine tremor in bilateral hands and hyperreflexia. There were no ocular or dermatologic 81 symptoms. Laboratory testing results included TSH <0.01 mcIU/mL (0.30-5.00 mcIU/mL), free 82 T4 3.6 ng/dL (0.6-1.6 ng/dL), free T3 15.2 pg/mL (2.2-3.9 pg/mL), thyroid stimulating 83 J o u r n a l P r e -p r o o f immunoglobulin 2.6 (< 1.3 TSI index)and thyrotropin receptor antibody 17 IU/L (0.00-1.75 IU/L) 84 (Table 1) . A thyroid scan with radioactive iodine uptake was not pursued. Her symptoms were 85 managed initially with a selective beta-blocker twice daily and, following results of antibody 86 testing, methimazole was prescribed. Thyroid function tests one month later were similar with 87 TSH 0.1 mcIU/mL (0.30-5.00 mcIU/mL) and free T4 3.2 ng/dL (0.6-1.6 ng/dL), prompting 88 increase in methimazole dose to 30 mg daily. Three months after diagnosis of GD patient was 89 seen in office for follow-up. Clinically euthyroid on exam, TSH was 0.01 mcIU/mL (0.30-5.00 90 mcIU/mL) with free T4 1.4 ng/dL (0.6-1.6 ng/dL). The patient continues to be managed 91 medically with thionamide titration and plans to trial discontinuation of beta-blocker. 

Graves' disease

Graves' disease: a population-based study of two Danish twin cohorts

Mechanisms of autoimmune thyroid diseases: From genetics to epigenetics

Infection and autoimmune thyroid disease

Infection, thyroid disease, and autoimmunity

Viruses and thyroiditis: an update

Presence of thyroid-stimulating hormone 127 receptor antibodies in a patient with subacute thyroiditis followed by hypothyroidism 128 and later Graves' disease with ophthalmopathy: A case report

Pathology of the thyroid in severe acute respiratory syndrome

Subacute thyroidits after Sars-134 COV-2 infection

A case of subacute thyroiditis associated with Covid-19 136 infection

Endocrine changes in SARS-CoV-2 patients and lessons from 138 SARS-CoV